BRPI0414907A - formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas - Google Patents

formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas

Info

Publication number
BRPI0414907A
BRPI0414907A BRPI0414907-6A BRPI0414907A BRPI0414907A BR PI0414907 A BRPI0414907 A BR PI0414907A BR PI0414907 A BRPI0414907 A BR PI0414907A BR PI0414907 A BRPI0414907 A BR PI0414907A
Authority
BR
Brazil
Prior art keywords
oral
pharmaceutical agent
injectable
microparticles
topical
Prior art date
Application number
BRPI0414907-6A
Other languages
English (en)
Inventor
Howard Bernstein
Donald E Chickering Iii
Eric K Huang
Sridhar Narasimhan
Shaina Reese
Julie A Straub
Original Assignee
Acusphere Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acusphere Inc filed Critical Acusphere Inc
Publication of BRPI0414907A publication Critical patent/BRPI0414907A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"FORMULAçõES FARMACêUTICAS COM LIBERAçãO SUSTENTADA INJETáVEIS, ORAIS OU TóPICAS". Formulações farmacêuticas e métodos são proporcionados para a distribuição sustentada de um agente farmacêutico a um paciente através de injeção, através de administração oral ou através de administração tópica. A formulação injetável inclui micropartículas porosas as quais compreendem um agente farmacêutico e um material de matriz em que, quando de injeção da formulação, uma quantidade terapêutica ou profilaticamente eficaz do agente farmacêutico é liberada das micropartículas durante pelo menos 24 horas. A formulação oral inclui micropartículas porosas as quais compreendem um agente farmacêutico e um material de matriz em que uma quantidade terapêutica ou profilaticamente eficaz do agente farmacêutico é liberada das micropartículas durante pelo menos 2 horas após administração oral. A formulação tópica inclui micropartículas porosas as quais compreendem um agente farmacêutico e um material de matriz em que uma quantidade terapêutica ou profilaticamente eficaz do agente farmacêutico é liberada das micropartículas durante pelo menos 2 horas após administração tópica.
BRPI0414907-6A 2003-09-30 2004-09-27 formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas BRPI0414907A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50738403P 2003-09-30 2003-09-30
PCT/US2004/031570 WO2005032523A1 (en) 2003-09-30 2004-09-27 Injectable, oral, or topical sustained release pharmaceutical formulations

Publications (1)

Publication Number Publication Date
BRPI0414907A true BRPI0414907A (pt) 2006-11-07

Family

ID=34421616

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414907-6A BRPI0414907A (pt) 2003-09-30 2004-09-27 formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas

Country Status (8)

Country Link
US (2) US20050069591A1 (pt)
EP (1) EP1667659A1 (pt)
JP (1) JP2007533634A (pt)
CN (1) CN1856296A (pt)
BR (1) BRPI0414907A (pt)
CA (1) CA2533887A1 (pt)
IL (1) IL173571A0 (pt)
WO (1) WO2005032523A1 (pt)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US6918561B2 (en) * 2002-10-31 2005-07-19 Yon So Chong Shell assembly for winding tire cord strip or belt cord strip
EP1589901A4 (en) * 2002-12-20 2006-08-09 Generipharm Inc INTRAKUTANE INJECTION
CA2542509A1 (en) * 2003-10-29 2005-05-19 Idexx Laboratories, Inc. Salts of pharmacologically active compounds
WO2006041908A2 (en) * 2004-10-08 2006-04-20 Noven Pharmaceuticals, Inc. Transdermal delivery of estradiol
DK1871353T3 (da) 2005-04-15 2011-04-04 Einstein Coll Med Vitamin k til forebyggelse eller behandling af hududslæt sekundært til anti-EGFR-terapi
CN106075449A (zh) 2005-07-14 2016-11-09 尼奥塞蒂克斯公司 用于局部脂肪组织治疗的持续释放的增强性脂肪分解性制剂
WO2007070843A2 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
US20070265329A1 (en) * 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
US9428582B2 (en) 2006-07-03 2016-08-30 Genmab A/S Method of treating rash in patients undergoing anti-EGFR therapy
US7772213B2 (en) * 2006-07-27 2010-08-10 Nathan Strick Composition for the treatment of inflammatory conditions
AU2007313077B2 (en) * 2006-10-17 2011-06-02 Neothetics, Inc. Methods, compositions, and formulations for the treatment of thyroid eye disease
EP1946746A1 (en) * 2007-01-17 2008-07-23 Merz Pharma GmbH & Co. KGaA Particulate aqueous system for the preparation of a formulation for the treatment of adipose diseases
NZ579362A (en) * 2007-02-02 2012-03-30 Univ Miami Therapeutic hybrid implantable devices
US20080194478A1 (en) * 2007-02-09 2008-08-14 Gene Signal International Sa Wound healing agent and composition
US20080227805A1 (en) * 2007-02-28 2008-09-18 Abbott Laboratories Sustained release parenteral formulations of buprenorphine
US8057381B2 (en) * 2007-04-16 2011-11-15 Allen Iii William F Method and implant material for treatment of urinary incontinence
US20090148498A1 (en) * 2007-05-14 2009-06-11 Sustained Nano Systems Llc Controlled release implantable dispensing device and method
US8071119B2 (en) * 2007-05-14 2011-12-06 Sustained Nano Systems Llc Controlled release implantable dispensing device and method
US20080292680A1 (en) * 2007-05-14 2008-11-27 Sustained Nano Systems Llc Hypercompressed polymer particles for controlled release ophthalmic medications
NZ599430A (en) * 2007-06-11 2014-03-28 Loch Macdonald R A drug delivery system for the prevention of cerebral vasospasm
US8252302B2 (en) * 2007-06-11 2012-08-28 Edge Therapeutics, Inc. Methods and compositions to treat hemorrhagic conditions of the brain
US8470360B2 (en) 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
US8815953B2 (en) 2008-03-13 2014-08-26 Spectrum Pharmaceuticals, Inc. Formulations of vitamin K analogs for topical use
US8697098B2 (en) 2011-02-25 2014-04-15 South Dakota State University Polymer conjugated protein micelles
WO2009143558A1 (en) * 2008-05-26 2009-12-03 Silphion Pty Limited Injectable formulations
WO2010119455A2 (en) * 2009-04-15 2010-10-21 Sun Pharma Advanced Research Company Ltd. An injectable sustained release pharmaceutical composition
US9132084B2 (en) * 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US10350364B2 (en) 2009-11-11 2019-07-16 Windgap Medical, Inc. Portable Drug Mixing and Delivery Device and Associated Methods
GB2487868B (en) * 2010-01-15 2014-12-10 Neothetics Inc Lyophilized cake formulations
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
UA111162C2 (uk) * 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
BR112013012994A2 (pt) 2010-11-24 2016-09-13 Lithera Inc formulações monoterapêuticas de beta-agonista de longa duração, lipofílicas e seletivas e métodos para o tratamento cosmético da adiposidade e saliência de contorno
CA2828253C (en) 2011-02-25 2016-10-18 South Dakota State University Polymer conjugated protein micelles
WO2012122535A2 (en) 2011-03-10 2012-09-13 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
JP6117811B2 (ja) 2011-10-31 2017-04-19 ゼリス ファーマシューティカルズ インコーポレイテッド 糖尿病を処置するための製剤
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
US10569017B2 (en) 2013-03-15 2020-02-25 Windgap Medical, Inc. Portable drug mixing and delivery device and associated methods
US9907910B2 (en) 2013-03-15 2018-03-06 Windgap Medical, Inc. Portable drug mixing and delivery device and associated methods
WO2014146060A1 (en) 2013-03-15 2014-09-18 Windgap Medical, Inc. Portable drug mixing and delivery system and method
CN110575445B (zh) * 2013-03-21 2023-08-18 优普顺药物公司美国分部 可注射的持续释放组合物及其用于治疗关节炎症及相关疼痛的方法
US9186817B2 (en) * 2013-08-01 2015-11-17 Sunny Pharmtech Inc. Method for preparing tobramycin sulfate powder
KR102428675B1 (ko) 2014-08-06 2022-08-02 엑스에리스 파머수티클스, 인크. 페이스트의 피내 및／또는 피하 주사를 위한 주사기, 키트, 및 방법
JP6462859B2 (ja) 2014-08-18 2019-01-30 ウィンドギャップ メディカル， インコーポレイテッド 携帯型薬剤混合及び送達装置並びに関連の方法
US11116903B2 (en) 2014-08-18 2021-09-14 Windgap Medical, Inc Compression seal for use with a liquid component storage vial of an auto-injector
CA3019104C (en) 2015-04-15 2023-09-26 Windgap Medical, Llc Removable actuating cap for use with an auto-injector assembly
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
CA2987081C (en) 2015-06-11 2022-08-30 Alrise Biosystems Gmbh Process for the preparation of drug loaded microparticles
CN116726183A (zh) * 2015-08-03 2023-09-12 Enb治疗公司 用于治疗与etbr激活相关的癌症的组合物和方法
JP6580777B2 (ja) 2015-08-13 2019-09-25 ウィンドギャップ メディカル， インコーポレイテッド 無菌特徴を有する混合及び注入装置
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
AU2016343952A1 (en) 2015-10-27 2018-05-10 Eupraxia Pharmaceuticals Inc. Sustained release formulations of local anesthetics
KR20170076965A (ko) * 2015-12-24 2017-07-05 롯데정밀화학 주식회사 히드록시프로필메틸 셀룰로오스 프탈레이트 입자 및 그 제조방법
EP3523021A1 (de) 2016-10-07 2019-08-14 Basf Se Sphärische mikropartikel
US20200009156A1 (en) * 2017-03-17 2020-01-09 Flexion Therapeutics, Inc. Fluticasone extended-release formulations and methods of use thereof
CN117085022A (zh) 2017-06-02 2023-11-21 Xeris药物公司 抗沉淀的小分子药物制剂
WO2019193094A1 (de) 2018-04-06 2019-10-10 Basf Se Sphärische mikropartikel
MX2021014450A (es) * 2019-05-29 2022-01-06 Camurus Ab Composiciones de liberacion controlada de lipidos.
US11607408B2 (en) * 2019-10-15 2023-03-21 Vanda Pharmaceuticals Inc. Method of treatment of schizophrenia
CN114903857B (zh) * 2021-02-09 2023-06-06 鲁南制药集团股份有限公司 一种荆防颗粒及其制备方法
CN115702880B (zh) * 2021-08-12 2023-11-03 山东新时代药业有限公司 一种重组甘精胰岛素注射液及其制备工艺
CN115813863A (zh) * 2022-12-15 2023-03-21 广州因明生物医药科技股份有限公司 一种可自发团聚的微球及其制备方法
CN116650444B (zh) * 2023-07-31 2023-10-31 国药集团川抗制药有限公司 一种他克莫司缓释药物及其制备方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005632A1 (en) * 1983-11-14 1989-06-29 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
ES2053549T3 (es) * 1986-08-11 1994-08-01 Innovata Biomed Ltd Un proceso para la preparacion de una formulacion farmaceutica apropiada para inhalacion.
US5690954A (en) * 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
ZA886284B (en) * 1987-08-31 1990-04-25 Advanced Polymer Systems Inc Controlled release formulations
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
US5205290A (en) * 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5403595A (en) * 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
US6060069A (en) * 1991-05-20 2000-05-09 Dura Pharmaceuticals, Inc. Pulmonary delivery of pharmaceuticals
US5327883A (en) * 1991-05-20 1994-07-12 Dura Pharmaceuticals, Inc. Apparatus for aerosolizing powdered medicine and process and using
US20030035845A1 (en) * 1992-06-11 2003-02-20 Zale Stephen E. Composition for sustained release of non-aggregated erythropoietin
AU680422B2 (en) * 1992-06-11 1997-07-31 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
DK0679088T3 (da) * 1992-09-29 2002-10-28 Inhale Therapeutic Syst Pulmonal levering af aktive fragmenter af parathyreoideaea hormon
GB9221329D0 (en) * 1992-10-10 1992-11-25 Delta Biotechnology Ltd Preparation of further diagnostic agents
DE69322789T2 (de) * 1992-10-19 1999-07-01 Dura Pharmaceuticals, Inc., San Diego, Calif. Trockenpulverinhalator
ES2231775T5 (es) * 1993-07-30 2011-02-02 Imcor Pharmaceutical Co. Composición de microburbujas estabilizadas para ecografía.
ATE212830T1 (de) * 1993-11-19 2002-02-15 Alkermes Inc Herstellung biologisch abbaubarer, einen biologisch aktiven stoff enthaltender, mikropartikel
GB9423419D0 (en) * 1994-11-19 1995-01-11 Andaris Ltd Preparation of hollow microcapsules
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6254854B1 (en) * 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
IE970588A1 (en) * 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
US7052678B2 (en) * 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
ATE248583T1 (de) * 1997-09-29 2003-09-15 Nektar Therapeutics In dosierinhalatoren verwendbare, stabilisierte zubereitungen
US6337092B1 (en) * 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
US6423345B2 (en) * 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
US6451349B1 (en) * 1998-08-19 2002-09-17 Quadrant Healthcare (Uk) Limited Spray-drying process for the preparation of microparticles
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6306425B1 (en) * 1999-04-09 2001-10-23 Southern Research Institute Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
US6610317B2 (en) * 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US7678364B2 (en) * 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US6743446B2 (en) * 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
US6585957B1 (en) * 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
EP1129705A1 (en) * 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Powder formulation for inhalation
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
US6589557B2 (en) * 2000-06-15 2003-07-08 Acusphere, Inc. Porous celecoxib matrices and methods of manufacture thereof
US7255865B2 (en) * 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
CA2433335C (en) * 2000-12-29 2010-04-20 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
GB0103348D0 (en) * 2001-02-10 2001-03-28 Medical Res Council Delivery of biologically active agents
US6551578B2 (en) * 2001-02-15 2003-04-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6544497B2 (en) * 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
ATE376803T1 (de) * 2001-04-06 2007-11-15 Bracco Research Sa Vorrichtung zur messung lokaler physikalischer parameter in einem flüssigkeitsgefüllten hohlraum
US6585967B2 (en) * 2001-07-05 2003-07-01 Closure Medical Corporation Adhesive treatment for tinea cruris
AU2003225057A1 (en) * 2002-04-19 2003-11-03 The Regents Of The University Of Michigan Polymer compositions that stabilize and control the release of formaldehyde-treated vaccine antigens
AU2003263024A1 (en) * 2002-04-23 2003-11-10 Christopher Mcconville Process of forming and modifying particles and compositions produced thereby
US6919068B2 (en) * 2002-05-17 2005-07-19 Point Biomedical Corporation Method of preparing gas-filled polymer matrix microparticles useful for echographic imaging
CN1694689A (zh) * 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US7658998B2 (en) * 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
US7511079B2 (en) * 2003-03-24 2009-03-31 Baxter International Inc. Methods and apparatuses for the comminution and stabilization of small particles
US7485283B2 (en) * 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging

Also Published As

Publication number Publication date
US20070264343A1 (en) 2007-11-15
CA2533887A1 (en) 2005-04-14
US20050069591A1 (en) 2005-03-31
CN1856296A (zh) 2006-11-01
WO2005032523A1 (en) 2005-04-14
IL173571A0 (en) 2006-07-05
JP2007533634A (ja) 2007-11-22
EP1667659A1 (en) 2006-06-14

Similar Documents

Publication Publication Date Title
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
BR0109875A (pt) Tratamento de doenças respiratórias
BRPI0408999A (pt) comprimidos prensados de multiparticulados de liberação oral prolongada
ECSP056076A (es) Sistema de suministro para droga y terapia celular
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
DE69906518D1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
AR045972A1 (es) Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
NO20043871L (no) Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid
MXPA03010991A (es) Composicion permeable a la piel que comprende inhibidor de ciclooxigenasa-a selectivo y alcohol monohidrico.
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
ATE418324T1 (de) Mucoadhäsive xyloglucan-haltige formulierung für medizinprodukte und pharmazeutische darreichungsformen
AR069572A1 (es) Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
HRP20110497T4 (hr) Postupci za primjenu kompozicija aminopiridina sa produženim oslobađanjem
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
WO2002034267A8 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
MXPA06000243A (es) Formulacion farmaceutica liofilizada estable de tetrodotoxina.
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
DE60336225D1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
BR0309057A (pt) Formulações lìquidas com baixa dosagem em entecavir e uso
ATE410152T1 (de) Therapeutisches system mit amoxicillin und clavulansäure
CO5261531A1 (es) Derivados de pleuromutilina y valnemulina usados para la fabricacion de un medicamento en el tratamiento transdermico de infecciones bacterianas en humanos y animales y composicion que los contiene

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.